NewsBiotech
Minerva Neurosciences Secures $200 Million to Advance Schizophrenia Treatment
Minerva Neurosciences (NERV) has secured up to $200 million in funding through a private placement to advance the development of roluperidon...
8 months ago
NewsBiotech
Galecto Acquires Damora Therapeutics: A New Focus on Blood Cancer Treatments
7 months agoUS
Galecto, Inc. (NASDAQ: GLTO) has completed its acquisition of Damora Therapeutics, a privately held biotech firm specializing in treatments for mutant calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPNs). This strategic move, accompanied by a $284.9 million Series C private placement, positions Galecto to advance Damora's portfolio, particularly DMR-001, a promising monoclonal antibody. The combined entity aims to provide safer, more effective therapies for blood cancer patients.
Key Insights
•
Acquisition Completed:: Galecto finalizes acquisition of Damora Therapeutics, expanding its pipeline in hematological cancers.
•
Financial Runway:: $284.9 million secured in Series C funding, expected to support operations into 2029.
•
Lead Program DMR-001:: DMR-001 shows significant potency against Type 2 mutCALR-driven cell proliferation in preclinical models.
•
Clinical Milestones:: IND submission for DMR-001 targeted for mid-2026, with Phase 1 proof-of-concept data anticipated in 2027.
•
Why This Matters:: The acquisition and funding provide Galecto with the resources to advance innovative treatments for MPNs, a group of rare and chronic blood cancers. Addressing mutCALR-driven MPNs, which affect approximately 42,000 patients in the US, could significantly improve patient outcomes.
In-Depth Analysis
Galecto's acquisition of Damora Therapeutics represents a strategic shift towards specialized treatments for hematological cancers. Damora’s lead candidate, DMR-001, a monoclonal antibody targeting mutCALR, has demonstrated 10-fold greater potency in preclinical models compared to reference molecules. This enhanced activity supports its potential to address a broad spectrum of mutCALR mutations in Essential Thrombocythemia (ET) and Myelofibrosis (MF).
The $284.9 million Series C private placement, led by Fairmount with participation from Viking Global Investors and others, ensures financial stability through 2029. This funding will support the advancement of DMR-001 through Phase 1 clinical trials, with first-in-human administration expected in mid-2026 and proof-of-concept data anticipated in 2027. Galecto also plans an IND for GB3226 in Q1 2026, further expanding its pipeline.
This acquisition not only broadens Galecto's portfolio but also leverages the expertise of both teams. The combined company aims to develop disease-modifying therapies that are both safer and more convenient for patients. The focus on mutCALR-driven MPNs addresses a critical unmet need, as these cancers are characterized by abnormal blood cell production and uncontrolled proliferation.
FAQs
What is DMR-001?
DMR-001 is Damora's lead candidate, a monoclonal antibody targeting mutant calreticulin (mutCALR) for treating Myeloproliferative Neoplasms (MPNs).
When is the IND submission for DMR-001 expected?
The IND submission for DMR-001 is expected in mid-2026.
What is the expected timeline for Phase 1 proof-of-concept data for DMR-001?
Phase 1 proof-of-concept data for DMR-001 is anticipated in 2027.
How does DMR-001 compare to other treatments?
DMR-001 has demonstrated approximately 10-fold greater potency against Type 2 mutCALR-driven cell proliferation compared to a reference molecule in preclinical models.
Key Takeaways
•
Galecto's acquisition of Damora Therapeutics marks a significant step in advancing treatments for blood cancers, particularly MPNs.
•
The $284.9 million funding ensures the company can progress its pipeline through critical clinical milestones.
•
DMR-001, the lead program, shows promise with enhanced potency in preclinical studies.
•
Key dates to watch include the IND submission in mid-2026 and Phase 1 data in 2027.
Discussion
What are your thoughts on Galecto's acquisition and its potential impact on blood cancer treatments? Share this article with others who need to stay ahead of this trend!
Related Articles
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer